Sarcoma treatment adherence and survival study
Part of Cancer clinical trials.
This study looks at how closely patients in the Strasbourg area follow their sarcoma treatment plans and how that affects their survival. Sarcoma is a rare type of cancer that starts in the body's connective tissues, like fat, muscle, or blood vessels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a soft tissue or visceral (internal organ) tumor, not a bone tumor, GIST (a rare stomach or intestine tumor), or Kaposi sarcoma.
- You were first seen by a multidisciplinary tumor board (a team of specialists) between January 1, 2017 and December 31, 2024.
- You were treated or followed in the Alsace-Moselle region of France.
- You agree to allow your medical data to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
This trial tests whether taking a special medication (5-ALA) before surgery makes the sarcoma glow under a special light, helping the surgeon see and remove the cancer more completely. The goal is to reduce the chance of leaving any cancer behind.
This study tests a personalized exercise program to help young sarcoma survivors become more physically active. If you join, you'll get support to increase your activity, which may improve your health and well-being.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.